





































































































































activate	the	immune	system	(4).	 	 	 	
Based	on	the	structure	of	the	constant	region,	immunoglobulins	are	divided	into	five	
major	classes;	IgG,	IgA,	IgM,	IgD	and	IgE.	It	is	the	structure	of	the	heavy	chains	that	
decides	which	class	an	antibody	belongs	to.		
	
	
Subclasses	of	immunoglobulins	
	
IgG	–	gamma	heavy	chains	
IgG	accounts	for	about	10-20%	of	plasma	protein,	and	is	the	major	class	of	the	five	
classes	of	immunoglobulins.	We	also	find	it	in	lymph	fluid,	cerebrospinal	fluid	and	
peritoneal	fluid.	It	can	bind	different	types	of	pathogens;	bacteria,	viruses	and	fungi	and	
neutralize	them	through	the	process	of	phagocytosis	and	ADCC	(antibody	dependent	cell	
mediated	cytolysis).	IgG	also	activates	the	complement	system.	Another	important	
feature	of	IgG	is	that	it	is	the	only	antibody	that	can	pass	through	the	placenta	to	provide	
protection	to	the	fetus	in	utero.	There	are	four	subtypes	of	IgG,	all	playing	different	parts	
in	the	immune	response.	Determination	of	subclasses	may	be	useful	to	diagnose	a	
potential	antibody	deficiency	(4,	5).	
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IgA	–	alpha	heavy	chains	
Of	all	immunoglobulins	in	secretions,	such	as	saliva,	tears	and	gastric	fluids,	IgA	is	the	
most	important.		IgA	is	a	neutralizing	antibody,	and	can	attach	to	and	penetrate	surfaces	
of	invading	pathogens,	mainly	protecting	us	against	gastrointestinal	and	respiratory	
microorganisms.	In	humans,	there	are	two	subtypes	of	IgA:	IgA1	and	IgA2.		IgA1	makes	
up	for	approximately	85%	of	total	IgA	concentration	in	serum.	It	has	a	good	immune	
response	to	protein	antigens,	whereas	IgA2	plays	an	important	role	in	the	mucosa	of	the	
eyes,	airways	and	GI-tract	fighting	against	polysaccharide-	and	lipopolysaccharide-
antigens.	In	blood	and	tissue	fluids	IgA	can	be	found	as	a	monomer,	but	in	secretions,	
such	as	saliva,	tears,	milk	and	gastric	fluids	IgA	is	dimeric.	,	In	these	secretions,	IgA	is	
actively	secreted	where	it	effectively	aggregate	antigens	and	prevent	their	penetration	
of	the	body	surface	(6).	
	
	
IgM	–	mu	heavy	chains	
IgM	is	constructed	by	five	monomers,	and	can	in	theory	have	10	antigen	binding	sites.		
These	units	each	comprise	two	heavy	chains	and	two	light	chains,	and	IgM	is	the	largest	
antibody	in	the	circulatory	system.	Due	to	the	size,	IgM	cannot	transverse	blood	vessels,	
and	is	restricted	to	the	blood	stream.	IgM	is	the	first	antibody	produced	in	response	to	
an	antigen,	and	is	the	most	effective	immunoglobulin	in	the	early	stages	of	disease,	being	
responsible	for	agglutination	and	cytolytic	reactions.	This	makes	IgM	very	efficient	in	
neutralizing	microorganisms,	and	prevents	further	spread	of	disease.	Because	IgM	is	
found	in	the	serum	without	any	prior	contact	with	an	antigen	it	is	also	called	a	“natural	
antibody”	(7,	8).		
	
	
IgD	–	delta	heavy	chains	
As	a	part	of	an	ancestral	surveillance	system,	IgD	is	involved	in	microbial	sensing	and	
immune	activation.	IgD	is	expressed	in	the	membrane	of	immature	B-lymphocytes,	also	
known	as	B-cells.	IgD	participate	in	the	activation	of	B-cells,	a	role	IgD	share	with	IgM.	
The	functional	difference	between	IgM	and	IgD	action	on	B-cells	is	not	clear.	Similar	to	
IgA,	IgD	is	also	produced	in	a	secreted	form,	which	can	be	found	in	blood	plasma.	It	has	
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been	found	that	a	class	switch	from	IgM	to	IgD	takes	place	in	the	upper	respiratory	tract	
where	IgD	activates	basophilic	granulocytes	and	mast	cells,	which	gives	a	layer	of	
mucosal	protection.	The	total	function	of	IgD	is	not	completely	understood,	and	research	
is	ongoing	(9,	10).	
	
	
IgE	–	epsilon	heavy	chains	
This	antibody	controls	allergic	reactions,	and	can	only	be	found	in	mammals.	It	is	the	
least	abundant	isotype	of	all	antibodies,	but	can	trigger	the	most	powerful	immune	
reactions.	IgE	secretion	leads	to	activation	of	mast	cells	and	basophilic	granulocytes.	
These	cells	have	specialized	surface	receptors,	called	Fc-epsilon-receptors.	When	IgE-
molecules	attach	to	these	receptors,	the	cells	become	activated.	This	again	leads	to	the	
release	of	different	substances	such	as	histamine,	serotonin,	proteases	and	different	
cytokines,	which	are	stored	inside	the	cells.	This	is	called	degranulation,	and	leads	to	a	
wide	spread	allergic	reaction	in	the	vascular	system	and	surrounding	tissue	with	
vasodilation	and	increased	permeability	of	the	blood	vessels.	This	reaction	is	called	
anaphylaxis,	and	can	give	circulatory	shock	within	a	few	minutes.	IgE	also	plays	an	
important	role	in	the	host	defense	against	parasites,	as	it	induce	phagocytic	cells	to	
localize	and	neutralize	pathogens	(11,	12).		
	
	
The	antibody	–	antigen	reaction	
	
Antibodies	bind	to	antigens	via	non-covalent	forces.	These	forces	are	dependent	on	a	
short	distance	between	the	sites	that	interact.	A	good	3D	fitting	between	the	antigen-	
antibody	binding	sites	is	therefore	essential.		Another	important	feature	is	that	a	non-
covalent	force	is	reversible	.	That	means	that	an	antibody-antigen	complex	also	can	
dissociate	(13).		
This	equilibrium	reaction	can	be	illustrated	as	followed:	
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This	equilibrium	presupposes	a	continuous	association	and	dissociation	between	the	
epitopes	and	the	paratopes.	Several	factors,	such	as	temperature,	pH,	ionic	strength,	
enzyme	treatment,	concentration	of	antibodies	and	antigens,	number	of	antigen	sites	
per	cell	and	duration	of	incubation	can	affect	the	reaction	between	an	antigen	and	an	
antibody	(8).		
The	strength	of	the	binding	and	the	affinity	depends	on	in	which	direction	the	
equilibrium	is	pushed.	It	can	either	be	pushed	towards	the	formation	of	an	immune	
complex,	or	the	dissociated	single	components.	The	concentration	of	immune	complexes	
and	the	single	components	at	equilibrium	can	be	expressed	by	the	equilibrium	constant,	
K	(Figure	7)	(8).	
	
	
Figure	7:	The	expression	of	the	equilibrium	constant,	K	(8).	
	
Temperature	is	a	factor	of	great	importance	when	it	comes	to	affecting	the	equilibrium	
constant.	In	practice,	we	can	see	this	when	performing	immunohistochemistry	(8).	If	we	
have	a	problem	with	the	antibody	binding,	a	good	solution	to	the	problem	might	be	to	
incubate	the	sections	with	antibodies	at	a	lower	temperature	over	a	longer	period	of	
time.		
	
The	immune	system	
	
The	most	important	function	of	the	humoral	immune	system	is	the	production	of	
antibodies.	The	system	is	organized	into	primary	and	secondary	lymphoid	organs.	The	
primary	lymphoid	organs	comprise	the	red	bone	marrow	and	the	thymus	gland.	In	the	
bone	marrow,	the	formation	of	lymphocytes	takes	place,	and	progenitor	cells	
differentiate	into	mature	B-lymphocytes,	or	B-cells	(bone	marrow	derived	lymphocytes).	
Some	of	the	progenitor	cells	travel	to	the	other	primary	lymphoid	tissue,	the	thymus,	to	
differentiate	and	mature.	These	cells	are	called	the	T-lymphocytes,	or	T-cells	(thymus-
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derived	lymphocytes)	(14).		Both	the	B-	and	the	T-lymphocyte	is	derived	from	the	
lymphoid	progenitors,	which	represents	the	adaptive	immunity	(Figure	8)	(15).	
Lymph	nodes,	tonsils	and	the	spleen	are	major	secondary	lymphoid	organs	(SLOs).	This	
is	where	the	lymphocytes	interact	with	each	other	and	other	non-lymphoid	cells.	In	
addition,	we	have	tertiary	lymphoid	structures	(TLSs).	In	TLSs,	lymphoid	cells	
accumulate	and	organize	themselves	in	structures,	which	are	similar	to	the	SLOs,	
without	being	encapsulated.	Immune	cells	have	been	found	to	form	TLSs	during	chronic	
inflammatory	reactions.	It	is	well	established	that	TLSs	can	be	found	in	chronic	
inflammatory	diseases,	such	as	rheumatoid	arthritis,	and	recently	also	in	cancers	(16,	
17).	
Before	the	lymphocytes	are	released	into	the	blood-	and	lymph,	they	undergo	a	strict	
process	of	selection.	This	process	tests	and	selects	cells	that	can	recognize	foreign	
material	from	the	body	itself.	If	the	lymphocytes	were	to	attack	and	destroy	healthy	
body	tissue	by	mistake,	the	consequences	would	be	severe.		That	is	why	most	
lymphocytes	die	soon	after	development	without	ever	functioning.		
The	B-	and	T-lymphocytes	carry	out	the	two	broad	classes	of	adaptive	immune	
responses,	the	antibody	responses	and	T-cell	mediated	immune	responses,	respectively	
(8,	12).	
	
	
	
	 10	
Figure	8:	The	hierarchy	of	hematopoietic	cells	(15).	
	
T-lymphocytes				
The	T-lymphocytes	produced	in	the	bone	marrow	leave	the	bone	marrow	at	an	early	
stage,	and	continue	their	development	in	the	thymus	gland.	During	the	process	in	the	
thymus,	the	T-lymphocytes	(or	thymocytes,	or	T-cells)	develop	a	T-cell	receptor	(TCR).	
The	development	of	the	TCRs	is	antigen-independent.		
The	development	of	the	receptor	is	a	multi-step	process	that	includes	positive	selection	
in	the	cortex	of	the	thymus,	where	the	T-cells	with	moderate	or	strong	binding	of	their	
TCR	to	epithelial	cells	moves	on	to	the	next	round,	whereas	T-cells	with	weak	or	no	
binding	dies.	In	the	next	round	the	binding	to	self-antigen	is	tested.	This	happens	with	
help	from	dendritic	cells,	macrophages	and	other	cells	in	the	thymus.	T-cells	with	strong	
binding	of	their	TCR	to	self-antigen	die	and	T-cells	with	moderate	or	weak	binding	to	
self-antigen	live.	This	is	called	negative	selection.	Both	the	epithelial	cells	in	the	cortex,	
and	the	other	cells	helping	in	this	process	contain	a	Major	Histocompatibility	Complex	
(MHC)	that	presents	antigen,	binds	to,	and	test	the	TCR	(13,	18).		
A	special	feature	with	the	T-cells	is	that	they	only	react	when	foreign	material	is	
localized	in	the	membrane	of	other	cells.	As	opposed	to	the	B-cells,	the	T-cells	cannot	
react	to	antigens	in	soluble	form.	To	develop	their	effector	functions,	the	T-cells	have	to	
cooperate	with	other	types	of	cells	called	professional	antigen	presenting	cells	(pAPC).		
The	pAPC	includes	macrophages,	dendritic	cells	and	B-cells.	The	pAPCs	constantly	
sample	the	environment	for	antigens.	If	they	find	an	antigen,	their	intracellular	
machinery	breaks	down	the	molecules	and	makes	them	recognizable	to	T-lymphocytes	
by	presenting	them	on	MHC.	In	addition	they	shuttle	antigens	from	tissues	to	SLOs	(19).	
All	T-cells	have	the	co-receptors	CD4	and	CD3.	During	the	development	in	the	thymus,	
the	T-cells	also	become	either	CD4-positive	or	CD8-positive.	These	are	also	co-receptors	
giving	the	T-cell	different	effector	functions.	CD8+-T-cells	are	also	called	cytotoxic	T-
cells.	They	contain	stored	lytic	granules,	filled	with	cytotoxins.	When	a	CD8+-T-cell	
arrives	at	a	site	of	infection,	they	recognize	peptides	presented	via	MHC	by	infected	cells.	
When	the	CD8+-T-cell	binds	to	the	MHC-molecule,	it	releases	the	cytotoxins	from	the	
lytic	granules,	and	the	target	cell	starts	to	die.	The	CD8+-T-cell	then	moves	on,	produces	
more	cytotoxins	and	is	ready	to	kill	the	next	target.		
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CD4+-T-cells	are	subdivided	into	two	groups,	called	CD4+Th1	cells	and	CD4+Th2-cells.	
These	cells	are	distinguished	by	the	sets	of	cytokines	they	make	and	which	effect	they	
have	on	the	immune	response.	The	Th1-cell	develops	a	cell-mediated	immune	response,	
working	with	macrophages.	They	help	the	macrophages	to	become	more	efficient	in	the	
killing	of	pathogens	at	the	infection	site.	The	Th2-cells	develops	an	antibody-mediated	
immune	response,	working	with	B-cells.	They	help	the	B-cells	to	proliferate	and	form	
plasma	cells.	This	is	why	these	cells	are	also	called	helper	Th2-cells	(18,	20).	(Figure	9)		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	9:	The	three	types	of	effector	T-cells	(20)	
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B-lymphocytes	
The	B-lymphocytes	are	produced	in	the	red	bone	marrow,	and	finish	their	maturation	
here,.	They	are	called	B-lymphocytes,	or	B-cells	because	they	finish	the	maturation	in	the	
bone	marrow.	During	the	maturation	the	immature	B-cells	develop	an	antigen-receptor	
called	B-cell	receptor	(BCR).	The	BCR	is	different	in	each	B-cell	clone,	and	can	be	
produced	in	millions	of	forms.	The	development	of	the	BCR	is	(similar	to	the	TCR)	
independent	of	antigens,	but	have	the	ability	to	interact	with	antigens	when	the	B-cell	
has	settled	in	a	secondary	lymphoid	organ.	The	BCR	may	be	better	known	as	
immunoglobulin,	or	antibodies!		
During	the	maturation	of	B-cells	the	BCR	are	rearranged	through	a	series	of	events	
including	rearranging	of	the	immunoglobulin	genes.	B-cells	are	also	tested,	and	the	cells	
that	bind	to	self-surface	antigens	are	removed	by	negative	selection.	When	tested	and	
approved,	immature	B-cells	migrate	to	the	peripheral	lymphoid	organs,	to	see	if	they	
find	any	cells	to	interact	with	(20).	
In	the	lymph	node	(or	any	other	peripheral	lymphoid	tissue	such	as	TLSs),	the	B-cell	
interacts	with	follicular	dendritic	cells	(fDC),	antigens	and	cytokines.	This	drives	the	
maturation	of	B-cells.	Mature	B-cells	that	interact	with	antigens	activate	and	start	
producing	daughter	cells	that	share	the	same	antigen	specificity.	This	is	called	clonal	
expansion	and	leads	to	the	formation	of	germinal	centers	in	the	lymph	node.	The	B-cell	
differentiates	to	plasma-	or	memory	cells.	Plasma	cells	are	examples	of	B-effector	cells,	
and	the	only	function	they	have	is	to	secrete	large	amounts	of	antibodies.		One	can	
distinguish	between	an	immature	and	a	mature	B-cell	by	biomarkers.	Immature	B-cells	
typically	expresses	CD10	and	CD34,	whereas	mature	B-cells	express	CD20	and	CD22	
(21).		
Antibodies	are	not	in	themselves	toxic	or	dangerous	to	pathogens.	The	mission	of	the	
antibodies	is	simply	to	bind	tightly	and	hold	on	to	the	antigens	of	the	pathogens.	By	
doing	this,	several	things	could	happen:	
	
1. Neutralizing	viruses	and	toxins	by	binding	to	the	surface	of	the	pathogen	and	
cover	it	up.	In	this	way	the	pathogen	cannot	bind	to	human	cells	and	cause	an	
infection.		
2. Opsonization	of	the	pathogen	by	binding	to	it	with	the	antigen	binding	sites,	and	
to	a	phagocytic	cell	with	the	Fc	region	promotes	phagocytosis.	When	the	antigen	
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is	marked	with	an	antibody,	phagocytic	cells	get	a	signal	to	“eat”	them.	In	this	way	
the	antigen	gets	degraded	and	can	not	cause	any	harm.	
3. Activate	the	complement	system	through	the	classical	pathway	which	leads	to	
further	promoting	of	phagocytosis	by	activating	the	complement	receptors	of	
phagocytes	(20).	
4. Antibody	dependent	cellular	cytotoxicity	(ADCC):	A	process	where	cytotoxic	
effector	cells	kill	antibody-coated	targets	via	a	non-phagocytic	pathway.	The	
process	is	characterized	by	the	release	of	the	cytotoxic	granules	or	by	expression	
of	cell	death-inducing	molecules.	NK-	cells,	monocytes,	macrophages,	neutrophils,	
eosinophils	and	dendritic	cells	are	cell	types	that	mediate	ADCC.	B-cells	and	B-
cell-tumors	are	destroyed	by	this	mechanism	when	treated	with	the	therapeutic	
monoclonal	antibody	Rituximab	(20,	22).	
	
After	the	termination	of	an	infection,	regulatory	mechanisms	stop	the	immune	response.	
This	allows	damaged	tissue	to	be	repaired	by	reducing	the	inflammation.	Effector	T-cells	
get	signals	to	die,	but	plasma	cells	are	allowed	to	persist.	This	means	that	pathogen-
specific	antibodies	can	maintain	in	the	circulation	for	years.	The	next	time	the	same	
pathogen	comes	along,	the	antibodies	are	ready	to	target	them	right	away,	and	the	body	
can	get	rid	of	the	infection	in	the	most	efficient	way.		
Long-lived	memory	B-cells	have	the	power	of	immunological	memory.	This	ensures	a	
faster	and	stronger	response	during	a	second	infection	(20).	
	
	
Secondary	lymphoid	orrans	(SLOs)	and	Tertiary	lymphoid	structures	(TLSs)	
In	SLOs,	the	B	and	T-cells	settle	in	different	areas.	These	are	called	the	B-	and	T-cell	
areas.	When	explaining	how	the	cells	are	organized,	the	lymph	node	is	a	good	example.	
In	lymph	nodes,	the	B-cell	area	is	located	in	the	cortex,	whereas	the	T-cell	area	is	in	the	
paracortical	region.		
The	SLOs	are	the	sites	where	mature,	naive	B-cells	encounter	specific	antigen.	When	this	
happens,	the	B-cells	are	in	the	T-cell	area,	and	become	activated	by	antigen-specific	Th2	
helper	cells.		The	T-cells	give	the	B-cells	signals	that	activate	them	and	make	them	
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proliferate	and	differentiate	further.	Naive	B-cells	can	also	become	activated	in	“their	
own”	zone	by	meeting	fDCs	in	the	germinal	centers	(20).		
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	10:	Schematic	structure	of	the	lymph	node	(20).	
	
	
The	clusters	of	lymphocytes	are	surrounded	by	specialized	blood	vessels	called	high	
endothelial	venules	(HEV),	which	through	most	of	the	lymphocytes	enter.	The	
lymphocytes	recognize	and	adhere	to	the	HEVs	via	cytokines,	and	squeeze	through	them	
and	arrive	at	the	cortical	regions	of	the	node.	HEVs	are	in	these	manner	key	players	in	
the	process	of	giving	an	appropriate	immune	response	by	sampling	lymphocytes	from	
the	blood	stream	so	that	the	lymphocytes	can	meet	other	cells	and	become	activated.		
The	entry	of	the	naïve	lymphocytes	is	controlled	by	dendritic	cells,	which	modulate	the	
phenotype	of	the	HEVs	(23).	
In	TLSs,	the	lymphocytes	also	settle	in	different	areas.	Typically,	TLSs	comprise	
aggregates	of	B-cells	in	a	network	of	follicular	dendritic	cells	(fDCs).	T-cells	and	HEVs	
surround	these	aggregates	(Figure	11).		Because	TLSs	are	not	encapsulated,	they	get	a	
direct	antigenic	stimulation	from	the	surrounding	environment.	This	difference	can	be	
of	importance	in	cancer.	In	solid	tumors	such	as	breast-,	ovarian-,	non-small-cell-lung-	
and	colorectal	cancer,	TLSs	have	been	described	(17,	24-26).	The	presence	of	these	
structures	is	supposed	to	be	associated	with	a	better	patient	outcome,	but	the	data	on	
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TLS	development	and	correlation	with	clinical	outcome	in	cancer	are	still	limited	(17,	
27).		
HEVs	have	recently	also	been	found	in	relationship	with	stroma	in	the	vicinity	of	human	
cancers.	This	is	of	great	importance	because	it	raises	the	possibility	that	naive	
lymphocytes	can	be	recruited	into	the	tumor	site,	where	the	pro-inflammatory	
environment	could	generate	cancer-destroying	effector	lymphocytes	without	
redistribution	of	the	lymphocytes	from	draining	lymph	nodes	(28).		
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	11:	Schematic	structure	of	TLSs	(17)	
	
Immunohistochemistry	can	be	used	to	visualize	how	the	lymphocytes	are	organized	in	
TLSs	(Figures	12	and	13).	
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Figure	12:	Immunohistochemistry	of	TLSs	in	human	colorectal	cancer.	In	figure	A,	T-cells	
are	stained	purple;	in	figure	B	CD20+	B-cells	are	purple.	In	figure	A-C,	CD21+	follicular	
dendritic	cells	are	stained	brown.	Figure	D	shows	brown-stained	DC-LAMP+	dendritic	cells.	
The	figure	visualizes	the	compartmentalization	of	the	different	cells.	The	Scale	bar	
indicates	100µm	(29).	
	
	
	
Principles	of	immunohistochemistry	
	
The	principle	of	immunohistochemistry	(IHC)	has	been	known	since	the	1930.	Coons	et	
al.	reported	the	first	IHC	study	in	1942,	in	which	they	identified	pneumococcal	agents	in	
infected	tissue	(30).	Today,	IHC	is	a	widely	used	method	for	localizing	antigens	in	
biologic	cells	or	tissues,	based	on	interaction	between	antigens	and	antibodies.	It	is	used	
for	disease	diagnosis,	drug	development	and	biological	research	(31).	Also,	antibodies	
are	very	selective	in	recognizing	their	antigens,	which	makes	them	a	perfect	tool	for	IHC.	
Under	natural	conditions,	antigens	induce	the	production	of	antibodies.	This	process	is	
imitated	when	the	antibodies	for	IHC	are	made.	Synthesized	antigens	with	the	structure	
of	a	naturally	occurring	protein	are	injected	into	host	animals	(rat,	sheep,	goat	etc.),	
which	then	produce	antibodies	against	the	synthesized	antigen	(32).		
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Direct-,	indirect-	and	sandwich	method	
The	IHC-technique	is	a	multi-step	process,	and	there	are	three	main	methods:	direct,	
indirect	or	enzymatic	(sandwich)	method.		First,	a	primary	antibody	must	bind	to	the	
tissue	antigen	one	wants	to	identify.	This	is	the	most	critical	antibody	because	without	
any	binding,	there	will	be	no	result.	Then,	a	secondary	antibody	must	bind	to	the	
primary	antibody.	Depending	on	the	type	of	experiment,	one	can	also	add	a	tertiary	
antibody.	In	the	indirect	method,	the	secondary,	or	tertiary	antibody	has	to	be	bound	to	
a	reporter-label	in	order	to	visualize	the	antigen	of	interest.	The	primary	antibody	is	
always	unlabeled	in	the	indirect	method	as	opposed	to	the	direct	method,	where	the	
label	is	attached	to	the	primary	antibody	(33).	
Direct	methods	are	one-step,	where	the	direct-labeled	antibody	binds	to	the	tissue	of	
interest.	The	antibodies	can	be	purchased	already	labeled,	or	the	researcher	can	label	
them	with	the	label	of	choice	(31).		
The	direct	method	is	pretty	straightforward	and	not	so	time-consuming	as	the	other	
methods,	but	is	also	usually	less	sensitive,	and	cannot	amplify	weak	signals.	It	addition,	
the	antibodies	may	be	tagged	with	a	label	not	suitable	for	future	applications.	This	is	
why	the	direct	method	is	less	used	compared	to	the	other	methods	(33).		
The	indirect	method	the	unlabeled	primary	antibody	is	added	to	react	with	the	tissue	
antigen.	When	the	secondary	antibody	is	added,	it	binds	to	and	reacts	with	the	primary	
antibody.	This	method	is	more	sensitive,	and	also	more	economic	because	the	secondary	
antibody	can	be	used	with	many	primary	antibodies	in	future	applications	(34).	
The	sandwich	method	uses	enzymatic	complexes	to	amplify	the	signal	and	detection	of	
the	primary	antibody	instead	of	labeled	antibodies.	This	is	by	definition	also	a	kind	of	
indirect	method.	In	this	method	the	secondary	antibody	acts	like	a	bridge	between	the	
primary	antibody	and	the	enzymatic	complex.	Just	like	the	cheese	between	the	bread	in	
a	sandwich.	The	main	sandwich	methods	are	called	the	avidin-biotin-complex	(ABC)	
method,	the	peroxidase-anti-peroxidase	(PAP)	method	and	the	alkaline	phosphatase	
anti	alkaline	phosphatase	(APAAP)	method	(33).	
In	addition,	polymers	are	also	used	in	the	polymer	based	two-step	method.	The	methods	
will	be	discussed	in	detail	later.	
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Enzymatic	chromogenic	and	fluorescent	labels	
The	type	of	label	used	in	the	direct	and	indirect	method	will	be	dependent	on	the	
expression	of	the	protein	of	interest.	If	the	protein	is	expressed	in	low	levels,	the	label	
needs	to	be	more	sensitive.	There	are	two	main	types	of	labels:	fluorescent	and	
chromogenic.		
The	fluorescent	method	uses	fluorochrome	labels	that	are	conjugated	to	antibodies.	This	
is	a	type	of	luminescence.	Two	commonly	used	fluorochromes	are	fluorescin	
isothiocyanate	(FITC)	and	tetramethyl	rhodamine	isothiocyanate	(TRITC).	Molecules	
with	luminescent	properties	emit	light	when	excited	by	light	of	a	shorter	wavelength.	It	
is	the	atomic	structure	of	the	fluorescent	materials	that	makes	them	give	off	light.	When	
the	electrons	absorbs	energy	from	a	photon,	they	become	“excited”	and	jumps	to	a	
higher,	unstable	level	of	energy.	During	this	jump,	the	electron	loses	some	amount	of	
energy	to	heat,	and	the	excess	energy	is	given	off	as	a	photon	as	the	electron	jumps	back	
to	the	lower	level	of	energy.	Many	wavelengths	of	light	can	excite	the	electrons	of	a	
fluorochrome,	but	every	fluorochrome	has	an	optimal	wavelength,	which	is	called	the	
excitation	peak.	The	excitation	peak	is	different	for	each	fluorochrome,	which	means	
that	different	fluorochromes	can	be	excited	by	the	same	wavelength.	The	fluorescence	
labeled	antibodies	bind	to	the	antigen	and	allows	antigen	detection	through	fluorescent	
methods.	For	example	confocal	microscopy	(35).	The	result	can	be	quite	beautiful.	
(Figure	13)		
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Figure	13:	Immunofluorescence	staining	of	oral	squamous	cell	carcinoma	tissue.	The	cells	
positive	for	plectin	are	stained	green,	and	the	cells	positive	for	uPAR	are	stained	red.	The	
mark	indicates	a	blood	vessel,	in	which	plectin	is	highly	expressed.	The	antibodies	used	was	
rabbit	anti-plectin	antibody	(ab83497,	Abcam,	Cambridge,	MA)	diluted	and	anti-human	
uPAR	antibody	(#3936,	Sekisui	Diagnostica,	Carpintera,	CA,	USA)	(36).	
	
The	chromogenic	detection	is	based	on	enzymes	and	their	chromogenic	substrates.	The	
antibodies	have	an	enzymatic	label	that	through	chemical	reactions	converts	colorless	
substrates	into	insoluble	particles	with	color.	These	particles	can	be	observed	under	the	
microscope.	The	four	most	commonly	used	enzymatic	labels	are	horseradish	peroxidase	
(HRP),	alkaline	phosphatase,	glucose	oxidase	and	beta-D-galactosidase.	The	most	
frequently	used	enzyme	is	HRP,	due	to	its	properties.	Its	small	size	gives	a	good	
intracellular	penetration.	It	also	has	a	fast	conversion	rate	of	chromogenic	substrates.	
DAB	(3,3’-diamino-benzidine)	which	gives	a	brown	color,	AEC	(3-amino-9-ethyl-
carbazole)	which	gives	a	red	color	and	CN	(4-chloro-1-naphthol)	which	gives	a	blue	
color,	and	are	examples	of	chromogenic	substrates	often	used	with	HRP	(37).	For	
strongly	expressed	antigens	the	DAB-substrate	will	give	a	long-lasting	staining	allowing	
the	slides	to	be	stored	(35).	
Both	the	enzymatic	chromogenic-	and	the	fluorescent	method	have	benefits	and	
detractions.	The	fluorescent	detection	has	a	shorter	procedure	and	good	resolution	to	
the	finest	details	but	will	fade	over	time	(photobleaching).	The	enzymatic	chromogenic	
detection	is	more	time-consuming,	has	lower	sharpness	and	contrast,	but	gives	more	
stable	colors	that	won’t	fade.	In	addition	there	are	no	limitation	to	the	tissue	type	
because	the	chromogenic	signals	are	not	affected	by	endogenous	autofluorescence	(32).	
	
	
Avidin	-biotin-complex	(ABC)	method	
Avidin	(naturally	found	in	egg	whites)	and	streptavidin	(naturally	found	in	the	
bacterium	streptomyces	avidinii)	are	structurally	similar	proteins	that	both	have	four	
binding	sites	for	biotin	(38,	39).	Therefore,	these	proteins	bind	strongly	and	with	high	
specificity	to	biotin.	Both	avidin	and	streptavidin	are	used,	but	streptavidin	is	a	recent	
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innovation	for	substitution	of	avidin.	When	streptavidin	is	used	in	the	ABC-method,	it	
sometimes	is	called	the	Labeled	StreptAvidin	Biotin	(LSAB)	method.	The	ABC	method	
for	antigen	detection	exploits	the	properties	of	avidin	or	streptavidin	by	using	
antibodies	conjugated	to	biotin.	A	biotin	molecule	is	conjugated	to	antibodies	and	
enzymes,	and	in	the	ABC-method	the	secondary	antibodies	are	conjugated	to	biotin.	We	
say	that	the	secondary	antibodies	are	biotinylated.	When	conjugated	to	the	antibodies,	
biotin	functions	as	a	bridge	between	the	tissue-bound	primary	antibodies	and	the	
avidin-biotin-peroxidase	complex.	In	this	way,	the	signal	from	the	primary	antibody	is	
amplified	(39)	(40)	(Figure	14).	
	
	
Figure	14:	Schematic	representation	of	the	ABC-staining	method	(41).	
	
	
The	peroxidase-anti-peroxidase	(PAP)	method	and	the	alkaline-phosphatase-anti-
alkaline-phosphatase	(APAAP)	method	
The	PAP-method	is	considered	very	sensitive	and	gives	good	results	even	with	low	
concentration	of	antibody.	It	is	on	the	other	hand	time-consuming	and	complicated	(8).		
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First,	a	primary	antibody	is	added	to	bind	to	the	tissue	antigen.	Then,	an	unconjugated	
secondary	antibody	is	added.	This	makes	it	possible	for	multiple	secondary	antibodies	to	
bind	to	one	primary	antibody.	A	tertiary	antibody	in	complex	with	peroxidase	is	added	
on	top	of	this.	And	again,	many	tertiary	antibodies	will	bind	to	one	secondary	antibody.	
This	gives	a	level	of	amplification	that	is	100-1000	times	greater	than	secondary	
antibody	amplification	(39).	The	PAP	complex	comprises	three	molecules	of	enzyme	
peroxidase	and	two	molecules	of	anti-peroxidase	(42)	(Figure	15).	
The	APAAP	method	is	the	companion	of	the	PAP-method,	and	works	in	the	same	way.	
The	difference	is	that	the	APAAP	complex	comprises	two	molecules	of	the	enzyme	
(alkaline	phosphatase)	and	one	molecule	of	the	antibody.	The	increased	number	of	
enzyme	per	antigen	binding	site	gives	increased	sensitivity	(42).	The	APAAP	method	is	
not	always	as	successful,	as	background	staining	can	be	a	problem	compared	to	the	PAP	
method	(43).	
	
	
	 	
	
	
	
	
	
	
	
Figure	15:	The	PAP	complex	method	(44).	
	
	
	
Polymer	based	two-step	method	
In	this	method,	the	secondary	antibody	is	conjugated	to	a	polymer.	This	method	is	
newer	than	the	previously	described	methods	as	it	was	developed	in	the	1990s.	The	
polymer	molecule	of	dextran	or	synthetic	peptide	is	coupled	to	an	enzyme	and	can	carry	
up	to	40	molecules	of	HRP,	which	gives	more	sensitivity,	efficiency	and	reliability	
compared	to	the	other	methods.	However,	the	dextran	molecule	occupies	a	larger	
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volume,	which	reduces	the	penetrative	ability	of	the	detection	reagent	in	aqueous	
environments	(45)	(Figure	16).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	16:	Scheme	of	polymer-based	technique	in	immunohistochemistry	(45).	
	
	
Working	with	antibodies	
	
There	are	several	things	to	keep	in	mind	when	working	with	antibodies.	One	of	the	
things	is	clonality.	In	the	Oxford	Dictionary	clonality	is	defined	as	“the	fact	or	condition	
of	being	genetically	identical,	as	to	a	parent,	sibling	or	other	biological	source”	(46).	This	
is	also	a	common	used	term	in	the	world	of	IHC,	as	antibodies	may	be	either	poly-	or	
monoclonal.		
Polyclonal	antibodies	are	generated	by	different	B-cell	clones,	but	are	directed	against	
various	epitopes	on	the	same	antigen	(47).	The	antibodies	are	collected	from	several	
different	B-cell	clones	that	have	been	activated	by	the	immune	system	of	the	host	
animal.	Animals	like	rabbit,	sheep,	goat,	rat	etc.	are	injected	with	a	specific	antigen	that	
makes	the	B-cell	clones	produce	antibodies	against	it.	When	the	sera	of	the	host	animals	
are	collected,	it	contains	a	heterogeneous	mixture	of	high	affinity	polyclonal	antibodies.	
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Monoclonal	antibodies	are	generated	by	a	single	B-cell-clone.	Hence,	they	are	a	
homogenous	population.	These	antibodies	are	identical,	and	recognize	a	single	epitope	
on	the	antigen.	If	the	antibody-producing	B-cell	is	fused	with	a	myeloma	cell,	the	unit	is	
immortalized	and	can	give	a	constant	supply	of	antibodies	(48).	
Choosing	mono-	or	polyclonal	antibodies	in	IHC	depends	on	the	tissue	or	protein	the	
researcher	wants	to	examine.	Since	monoclonal	antibodies	are	highly	specific,	examples	
of	recommended	use	are	detecting	a	specific	antigen,	a	single	protein	or	to	stain	cells	
with	less	background	staining.	They	are	in	other	words	great	to	use	in	IHC.	Polyclonal	
antibodies	tend	to	have	more	non-specific	reactivity,	and	the	variability	from	batch	to	
batch	is	high.	The	polyclonal	antibodies	are	recommended	to	use	when	detecting	low	
levels	of	a	particular	antigen,	targets	in	solutions	and	denatured	proteins.	When	used	in	
IHC,	the	probability	for	background	staining	is	increased	compared	to	monoclonal	
antibodies	(49).		On	the	other	hand	are	polyclonal	antibodies	more	robust	when	used	on	
routinely	processed	tissue	specimens	(47).	
Mono-	and	polyclonal	antibodies	also	differ	in	what	is	called	cross-reactivity.	The	term	
“cross-reactivity”	describes	a	reaction	that	can	happen	when	an	antigen	reacts	with	
several	different	antibodies.	The	common	case	is	that	several	antigens	share	at	least	one	
common	epitope.	Cross-reactivity	can	also	occur	during	antigen	retrieval	(see	later)	
when	changes	in	one	or	several	epitopes	can	be	induced	by	accident	(47).	
A	third,	and	perhaps	the	most	important	example	of	cross	reactivity	in	IHC,	are	cross-
species	cross	reactivity.		
The	species	the	primary	antibody	is	generated	in	should	always	be	different	from	the	
species	of	the	tissue	or	protein	one	wants	to	detect.	If	you	are	going	to	detect	a	rat	
protein,	the	primary	antibody	must	not	be	generated	in	a	rat.	If	the	primary	antibody	
also	is	from	a	rat,	the	secondary	antibody,	which	is	added	later,	could	cross	react	with	
both	the	primary	antibody	and	endogenous	immunoglobulins	in	the	rat	tissue.	Needless	
to	say,	the	IHC-staining	will	not	be	successful.	A	primary	antibody	from	goat	would	be	a	
more	appropriate	choice.	
When	choosing	a	secondary	antibody,	it	should	be	against	the	host	species	of	the	
primary	antibody.	In	the	example	above,	the	secondary	antibody	would	be	anti-goat	
(50).		
A	final	thing	to	take	into	consideration	when	working	with	antibodies	is	the	dilution.	
When	the	antibodies	are	received	from	the	producers	they	are	highly	concentrated.	This	
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means	that	the	antibodies	have	to	be	diluted	and	adjusted	to	every	experiment	to	get	the	
optimal	contrast.	The	recommended	dilution	range	is	always	written	in	the	data-sheet	
that	follows	each	antibody,	which	makes	the	job	a	bit	easier.		
	
Method	and	work	process	
	
There	are	several	steps	in	the	procedure	for	immunohistochemical	staining.	These	steps	
may	have	to	be	adjusted	for	every	lab,	and	for	every	antibody	one	is	working	with.	The	
method	presented	is	based	on	my	own	work	in	the	laboratory.		
Before	I	could	start	my	experiments,	I	spent	some	time	reading	about	the	method	and	
learning	how	to	perform	IHC.	This	was	done	during	the	spring/summer	of	2015.	My	
supervisor	helped	me	to	find	the	correct	antibodies	and	the	antibodies	were	ordered	in	
September	2015.	The	experiments	were	performed	during	the	fall	of	2015	and	the	
project	was	finished	on	estimated	time	and	according	to	the	project	plan.		
In	my	first	experiment,	I	used	the	enzymatic	chromogenic	indirect	method;	with	HRP	as	
the	enzymatic	label,	and	in	my	second	experiment	I	used	the	polymer-based	two-step	
method	with	HRP	as	the	enzymatic	label.	My	third	and	final	experiment	was	a	double	
staining.	All	experiments	were	performed	in	the	laboratory	at	the	Tumorbiology	
Research	Group,	Institute	of	Medical	Biology,	Faculty	of	Health	sciences,	UiT	–	The	Arctic	
University	of	Norway.		
In	my	first	experiment	(experiment	nr.1),	I	used	the	general	procedure	for	single	
staining	of	formalin-fixed-paraffin-embedded	(FFPE)	human	tissue	(51).	I	performed	the	
staining	on	human	lymph	nodes,	aiming	to	stain	HEVs,	which	has	earlier	been	
performed	successfully	by	several	research	groups	on	different	tissues	(52)	
(53).		Because	of	physiology	earlier	described,	a	human	lymph	node	would	be	a	positive	
control,	and	I	would	expect	to	find	HEVs	in	the	lymph	node.	I	also	included	a	negative	
control,	which	were	not	incubated	with	the	primary	antibody.	It	was	important	to	
validate	this	procedure	ahead	of	the	later	doublestaining.		
When	working	with	formalin-fixed	sections,	they	have	to	be	boiled	in	citrate-buffer	with	
pH	6	for	20	minutes.	This	boiling	will	break	the	protein	cross-links	formed	by	formalin	
fixation,	and	uncover	hidden	antigens.	This	is	called	antigen	retrieval.	This	step	is	not	
necessary	if	the	sections	are	fixed	in	zinc	or	other	mediums	(step	2)	(54).		
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For	my	primary	antibody	I	used	rat-anti-peripheral	node	adressin	(PNAd),	clone	MECA-
79,	Biolegend,	San	Diego	with	a	dilution	of	1:25.	This	antibody	recognizes	PNAd	that	is	
expressed	on	HEV	of	lymphoid	tissues,	chronic	inflamed	tissues	and	rheumatoid	synovia	
(55).		For	my	secondary	antibody,	I	used	HRP-labeled	goat	anti-rat	light	chain	antibody,	
#AP202P,	Millipore,	Temecula,	CA	with	a	dilution	of	1:250.	To	dilute	the	antibodies,	one	
can	use	different	blocking	solutions.	Depending	on	the	origin	of	the	secondary	antibody,	
the	blocking	solution	can	be	made	of	different	sera.	These	sera	carry	antibodies	that	
bind	to	reactive	sites,	and	prevent	non-specific	binding	of	the	secondary	antibodies.	The	
serum	has	to	be	from	the	species	that	the	secondary	antibody	was	generated	in.	In	my	
experiment,	the	secondary	anti	body	was	generated	in	goat,	so	I	used	1,5%	goat	serum	
diluted	in	PBS	for	my	blocking	solution	(51,	56).	
In	the	protocol,	there	are	several	steps	where	the	sections	are	washed	in	phosphate-
buffered	saline	(PBS).	This	is	an	isotonic	buffer	that	matches	the	osmolality	and	ion-
concentration	of	the	human	body,	and	helps	to	maintain	a	constant	pH	(57).	For	
detection,	I	used	Vectastain	elite	ABC-Kit,	Vector	Laboratories,	#PK-6100,	Burlingame	
CA,	which	gives	a	red	color.	Finally,	the	sections	were	counterstained	with	Harris	
hematoxylin	(Sigma-Aldrich,	St.	Louis,	MO).	
	In	my	second	experiment	(experiment	nr.	2)	I	aimed	to	stain	myeloid	dendritic	cells	
positive	for	the	biomarker	CD11c,	also	known	as	integrin	alpha	X.	CD11c	is	not	only	
expressed	by	dendritic	cells	but	also	on	tissue	macrophages	(58).	Research	groups	have	
successfully	stained	CD11c+	dendritic	cells	using	IHC	(59).	A	human	lymph	node	would	
serve	as	a	positive	control	for	the	CD11c+	dendritic	cells	too	and	a	negative	control	was	
also	included..	In	this	experiment	I	also	used	the	general	procedure	for	single	staining,	
working	with	FFPE-tissue.	For	my	primary	antibody	I	used	rabbit	anti-human	CD11c,	
#AHP1226,	AbD	Serotec,	North	Carolina	with	a	dilution	of	7,5	micrograms/ml.	For	the	
secondary	antibody	I	used	labeled	polymer	HRP-anti	Rabbit	from	the	Dako	EnVision+	
System-HRP	(DAB),	Dako	North	America	inc.,	Carpinteria,	CA	for	use	with	rabbit	
primary	antibodies.	For	detection,	diaminobenzidine	(Dako	EnVision	+	System-
Horseradish	Peroxidase,	Dako)	were	used,	which	gives	a	brown	color.		
It	was	not	random	that	both	experiments	1	and	2	had	the	same	positive	control.	In	my	
third	experiment	(experiment	nr.	3),	the	double	staining,	the	aim	was	to	detect	both	
HEVs	and	CD11c+	dendritic	cells	in	a	human	lymph	node	at	the	same	time.	I	developed	a	
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protocol	combining	the	protocol	from	the	two	experiments	above	to	perform	this	
specific	staining	(see	below).		
	
	
Protocol	for	single	staining	
This	is	the	general	protocol	for	FFPE-tissue	described	step-by-step.		
Before	staining,	all	sections	have	to	be	incubated	overnight	at	60°C	to	melt	the	paraffin.	
	
1. To	deparaffinize	further,	the	sections	are	sent	through	a	series	of	baths	with	
xylene	and	alcohol,	and	finally,	distilled	water.		
2. Boil	in	citrate	buffer	for	20	minutes		
3. After	the	boiling,	the	sections	have	to	gradually	cool	down.	Let	the	sections	cool	
down	in	the	hot	citrate-buffer	for	20	minutes.	Then,	add	running	distilled	water,	
for	10	minutes.		
4. Incubate	the	sections	with	3%	H2O2	diluted	1:100.	This	is	to	block	endogenous	
peroxidase	activity	in	other	cells	than	the	ones	of	interest.	By	doing	this,	the	
background	staining	is	reduced.	
5. Wash	in	3	x	5	minutes	in	PBS	
6. Incubate	with	blocking	solution.		
7. Incubate	with	the	primary	antibody	for	30	minutes-1hour	in	room	temperature	
8. Wash	3	x	5	minutes	in	PBS	
9. Incubate	with	the	secondary	antibody	for	30	minutes	in	room	temperature	
10. Wash	3	x	5	minutes	in	PBS	
11. Incubate	with	the	chromogenic	substrate	solution	for	10	minutes	
12. Wash	3	x	5	minutes	in	PBS	
13. Wash	in	hematoxylin	for	30	seconds.	The	hematoxylin	has	to	be	filtered	to	
remove	precipitates	
14. Wash	in	Scotts	solution	for	15	seconds	
15. Dehydrate	the	sections	by	sending	them	through	a	series	of	baths	with	alcohol	
and	xylene,	in	the	opposite	order	from	when	the	sections	were	deparaffinized.		
16. Mount	with	histokit.		
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Double	staining	protocol	for	CD11c+	dendritic	cells/	PNAd+	HEVs	
The	protocol	is	based	on	the	previously	described	protocol	for	single	staining,	with	some	
changes	to	get	a	good	enough	contrast	between	the	two	cell	types.	It	turned	out	to	be	a	
two-day	procedure.		
I	started	with	the	staining	of	the	HEVs	and	followed	the	single	staining	protocol	down	to	
step	seven	using	the	rat-anti-	PNAd	primary	antibody.	In	step	seven	I	changed	the	
incubation	of	the	primary	antibody,	from	30	minutes	–	1	hour	in	room	temperature	to	
overnight	in	the	refrigerator.	The	next	day	I	continued	with	step	8-12	using	the	goat	
anti-rat	light	chain	secondary	antibody.		Then,	I	added	an	extra	step	with	3%	H2O2	
diluted	1:100	to	block	endogenous	peroxidase	activity	and	washed	3x5	minutes	in	PBS.		
To	stain	the	CD11c+	dendritic	cells,	step	7-12	was	then	repeated	using	the	rabbit	anti-
human	CD11c	primary	antibody	and	the	labeled	polymer	HRP-anti	Rabbit	secondary	
antibody.	Finally,	step	13-16	was	performed.	Step	15	was	replaced	with	dehydration	in	
heat	cabinet	at	60°C	for	10	minutes.		
	
	
Multiple	staining	
Multiple	staining	is	of	interest	when	the	researcher	wants	to	look	at	the	localization	or	
presence	of	two	or	more	antigens	in	the	same	tissue	sample	or	even	in	the	same	cell.	
There	are	several	protocols	to	perform	multiple	staining,	and	in	my	experience,	the	
procedure	is	very	time-consuming.	In	general,	every	multiple	staining	protocol	is	a	
combination	of	single	staining	protocols	for	each	antibody.	One	must	be	very	aware	of	
cross-reactions	and	the	blocking	steps	as	the	researcher	now	works	with	more	than	two	
antibodies,	and	it	may	take	several	failed	experiments	to	find	the	right	incubation	times	
and	dilutions.	Another	problem	is	to	find	color	combinations	that	give	a	crisp	contrast	
(60).	
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Results	
	
Experiment	nr.	1:		
The	PNAd+	HEVs	were	stained	successfully	and	were	easy	to	spot	in	the	microscope.	As	
figure	17	shows,	the	red	color	gave	a	good	contrast	to	the	surrounding	cells	and	the	
HEVs	were	clear	and	well	defined.	The	picture	is	taken	at	40x	enlargement	and	shows	
three	HEVs	surrounded	by	lymphocytes,	which	have	a	purple	color	from	the	
hematoxylin	counterstaining.		
	
	
	
	
	
Figure	17:	Representative	IHC	staining	for	HEVs	surrounded	by	lymphocytes	in	a	human	
lymph	node	at	40	x	enlargement.	PNAd+	vessels	are	stained	red	and	cell	nuclei	are	stained	
blue	by	hematoxylin.	The	scale	bar	indicates	20µm.	
	
	
	
	
	
Experiment	nr.	2:	
The	CD11c+	dendritic	cells	were	stained	successfully,	and	they	appeared	really	clear	and	
defined	with	their	branches	in	the	microscope	as	shown	in	figure	18.	The	DAB-
chromogen	gave	a	really	good	contrast	to	the	surrounding	cells	and	the	dendritic	cells	
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were	easy	to	spot.	Figure	18	is	a	picture	taken	at	40	x	enlargement	and	shows	a	cluster	
of	CD11c+	dendritic	cells	surrounded	by	lymphocytes,	which	are	purple	from	the	
hematoxylin	counterstaining.		
	
	
Figure	18:	Representative	IHC	staining	of	a	cluster	of	CD11c+	dendritic	cells	surrounded	by	
lymphocytes	in	a	human	lymph	node	at	40	x	enlargement.	CD11c+	dendritic	cells	are	
stained	brown	and	cell	nuclei	are	stained	blue	by	hematoxylin.	The	scale	bar	indicates	
20µm.	
	
	
Experiment	nr.	3:	
The	double	staining	experiment	was	successful	and	the	HEVs	and	the	dendritic	cells	
were	easy	distinguishable.	The	chromogens	worked	well	together	and	gave	clear	defined	
colors	with	little	background	staining.	Figure	19	is	taken	at	20	x	enlargement	and	shows	
six	HEVs	in	a	cluster	of	dendritic	cells	with	their	branches.	Figure	20	is	from	the	same	
area	as	figure	19	but	is	taken	at	40	x	enlargement.	The	figure	shows	five	HEVs	in	a	
cluster	of	dendritic	cells.	In	both	figure	19	and	figure	20	the	CD11c+	dendritic	cells	and	
the	HEVs	are	surrounded	by	lymphocytes,	which	are	purple	from	the	hematoxylin	
counter	staining.		
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Figure	19:	Double	staining	of	CD11c+	dendritic	cells	and	HEVs	in	a	human	lymph	node	at	
20	x	enlargement.	PNAd+	vessels	are	stained	red	and	CD11c+	dendritic	cells	are	stained	
brown.	Cell	nuclei	are	stained	blue	by	hematoxylin.	The	scale	bar	indicates	50µm.	
	
	
	
	
Figure	20:	Double	staining	of	CD11c+	dendritic	cells	and	HEVs	in	a	human	lymph	node	at	
40	x	enlargement.	PNAd+	vessels	are	stained	red	and	CD11c+	dendritic	cells	are	stained	
brown.	Cell	nuclei	are	stained	blue	by	hematoxylin.	The	scale	bar	indicates	20µm.	
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Discussion	
The	immune	system	is	complex,	and	vital	for	production	of	antibodies.	
Immunohistochemistry	combines	two	disciplines;	immunology	and	chemistry	and	is	
now	one	of	the	most	used	special	procedures	in	pathology	departments.	The	
visualization	of	antibodies	that	have	bounded	to	specific	antigens	can	be	utilized	in	the	
aim	to	make	a	correct	diagnosis,	and	also	for	the	sake	of	prognostic	evaluation.	
In	diagnostic	pathology,	automatic	machines	have	more	or	less	standardized	protocols	
for	IHC.	Even	though	IHC	is	a	well-established	method,	there	is	no	standard	protocol	that	
will	work	for	all	antibodies	when	doing	manual	staining	with	antibodies	in	the	
laboratory.	This	leads	to	a	lot	of	trying	and	failing	before	the	right	antibody-dilutions	
and	incubation	times	are	settled.	Factors	as	temperature,	equipment	and	internal	
procedures	are	also	playing	a	role	and	every	lab	has	to	do	a	test-stain	with	different	
dilutions	to	find	what	works	best	in	their	lab.	There	can	also	be	difficulties	with	the	
antibodies,	as	different	batches	may	give	different	result.	There	is	also	the	risk	of	
contamination	of	the	antibody	mixture.	This	makes	IHC	a	time-consuming	and	
sometimes	difficult	procedure.	On	the	other	hand,	IHC	represents	in	most	cases	a	robust	
and	specific	method	to	detect	tissue	markers	and	plays	an	important	role	in	diagnostics.		
In	my	experiments	I	faced	some	difficulties	and	spent	some	time	troubleshooting.	I	had	
to	do	several	tests	with	different	dilutions	to	get	the	strength	of	the	staining	strong	
enough,	but	not	so	strong	that	the	slide	was	overstained.	Also	with	the	double	staining	
several	trials	had	to	be	completed	before	both	colors	could	be	visualized	at	the	same	
time.	It	is	important	to	work	together	with	experienced	technicians	and	also	to	have	the	
benefit	to	evaluate	slides	together	with	well-trained	pathologists.	When	I	first	found	the	
correct	dilutions	and	incubation-times,	the	procedures	were	pretty	straightforward	and	
it	was	very	satisfying	to	see	the	color	reaction	develop	before	my	eyes,	and	the	project	
was	finished	on	the	estimated	time.	The	protocols	are	understandable,	but	it	requires	
lab	training	and	some	background	information	to	understand	what	happens	when	
incubating	with	the	different	solutions.		
All	in	all	I	experienced	IHC	as	a	reliable	method	and	I	think	IHC	always	will	play	an	
important	role	in	research	and	diagnostics.	
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